UNIVERSITY OF PENNSYLVANIA
AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis is a funding opportunity from UNIVERSITY OF PENNSYLVANIA, up to 1336625, closing May 31, 2033.
May 31, 2033
(2496d left)Overview
Multiple sclerosis (MS), a chronic, immune-mediated disease affecting the central nervous system (CNS), impacts an estimated 2.5 million people worldwide and nearly 1 million in the USA, primarily young adults with a female predilection. It is a major cause of neurological impairment, characterized by relapses that…